Leviticus Cardio announces successful first in human case for its paradigm-shifting wireless heart pump system
Leviticus Cardio together with Jarvik Heart Inc. unveiled their groundbreaking wireless heart pump system to the public on 6 February 2019. Following years of development and animal testing, Leviticus announced the first successful implant of a Fully Implanted Ventricular Assist Device (FIVAD) in a human, which took place in December 2018 at the National Research Center for Cardiac Surgery in Astana, Kazakhstan. The patient was in the audience during a press conference, after being discharged from hospital and returned back home to a normal life.
At the press conference, top heart failure experts from around the world announced the successful implantation of FIVAD into a human. Prior to the conference, an article about the FIVAD implantation was published by the prestigious Journal of Heart and Lung Transplantation (JHLT). Among those who participated in the press conference was Harvard Medical School Professor Mandeep Mehra, Editor-in-Chief of JHLT.
We, the medical community, cardiologists, cardiac surgeons, VAD coordinators and the patients have wanted this for decades.
Professor Nir Uriel, Director of the University of Chicago Medical Center for Heart Failure, Transplant and Mechanical Circulatory Support
The ventricular assist device (VAD), an implanted mechanical circulatory pump, presents an alternative for the thousands of patients who are candidates for heart transplantation each year. VADs are increasingly in use to support patients with severe heart failure. VADs require connection to a continuous power source, which requires patients to have a a drive line (wire) coming out of their bodies. Patients with VADs are highly vulnerable to device-related infections and suffer a major reduction in quality of life, two issues that represent the most important challenges to extended VAD use.
The Leviticus FIVAD system comprises internal and external components is powered wirelessly, which allows patients to walk around without any physical impediments for up to eight hours a day. FIVAD incorporates a heart pump produced by Jarvik Heart Inc, a leading manufacturer of VADs.
Leviticus has developed a game-changing product in the VAD market. We look forward to their progress in making the FIVAD the gold standard for treatment that truly brings new hope to patients who suffer from severe heart failure. We are extremely proud of the Leviticus team and delighted to be a part of their journey.
Trendlines Chairman and CEO Steve Rhodes